- Web-meeting scheduled for November 1, 2017, at 4:15 p.m. ET
- 19 patents filed encompassing 44 countries
- Patents cover broad range of lipophilic bio-actives including cannabinoids, vitamins and other pharma
- Patented lipophilic delivery system proven to improve bio-absorption
The medical effectiveness of cannabinoids is no longer in question, and the cannabinoid market proliferates ever faster as more people realize the therapeutic benefits. However, the human gastrointestinal tract just doesn’t absorb cannabinoids effectively, and much of what is ingested is subsequently excreted by the body, causing onset times and efficacy to vary wildly.
With 19 patent applications filed internationally covering 44 countries, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has already been issued patents in the U.S. and Australia for the delivery of all non-psychoactive cannabinoids, immediately adding value and validation to the underlying science. Lexaria’s technology is a novel drug delivery platform believed to be applicable across a wide range of different drug types and vitamins, as well as cannabinoids. Lexaria’s lipophilic enhancement technology has been proven to increase both absorption and bioavailability of payload molecules, and the applications and implications are immense.
To clearly communicate this opportunity, Lexaria will host a web-meeting on November 1, 2017, at 4:15 p.m. ET. Lexaria will deliver all the latest news, and, as stated in its newsletter, the company is “expecting to have a LOT to talk about – don’t miss this!” The meeting is open to everyone, but pre-registration is required.
REGISTER here for this important event: https://events.genndi.com/register/169105139238467429/ce8311a9b6
The newsletter also emphasized the fact that Lexaria’s “technology is a delivery platform believed to be applicable to many different types of drugs, vitamins and other substances. It is the applicability of our tech in delivering a substance more efficiently that provides its most substantive value…” To expedite its value proposition, Lexaria has already instructed its attorneys to accelerate examinations of its multiple patent applications wherever possible.
Keeping with strategy, Lexaria is working on several parallel paths toward development of new products and new applications for its technology and seeking new technologies that complement its lipophilic delivery platform. Broad ranging applications will further feed Lexaria’s low-cost, high-margin license and royalty business model of revenue generation. The company’s first licensee is gaining considerable market traction utilizing and paying for its technology, and, with multiple royalty agreements already in the works, Lexaria should easily continue to expand its licensing network. Lexaria has no debt and maintains a healthy cash balance. The company believes it has sufficient cash to follow through with all of the expected R&D and product development, as well as to fund general corporate needs through to the end of 2018.
Lexaria’s novel lipophilic enhancement technology has implications across a wide swath of consumer and pharmaceutical delivery protocols. The global impact of Lexaria’s patented delivery system has barely begun, and it could quickly reverberate to the bottom line.
For more information, visit the company’s website at www.LexariaEnergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment